A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma

Oral Oncology

Volumn 53, Issue , 2016, Pages 74-79

  Bowles, Daniel W ^a   Keysar, Stephen B ^a   Eagles, Justin R ^a   Wang, Guoliang ^a   Glogowska, Magdalena J ^a   McDermott, Jessica D ^a   Le, Phuong N ^a   Gao, Dexiang ^b   Ray, Charles E ^a   Rochon, Paul J ^a   Roop, Dennis R ^c   Tan, Aik Choon ^a,b   Serracino, Hilary S ^a   Jimeno, Antonio ^a,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Food Science and Human Nutrition   (United States)

^c University of Colorado Anschutz Medical Campus   (United States)

Author keywords

Cetuximab; Combination therapy; Head and neck squamous cell carcinoma; Hedgehog signaling pathway; Phase 1

Indexed keywords

CETUXIMAB; PATIDEGIB; ANTINEOPLASTIC AGENT; SONIC HEDGEHOG PROTEIN;

ADULT; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GENE EXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; LIVER FUNCTION; LOADING DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUSCLE SPASM; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; TUMOR BIOPSY; TUMOR REGRESSION; TUMOR VOLUME; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENETICS; HEAD AND NECK NEOPLASMS; PILOT STUDY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CETUXIMAB; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; HEAD AND NECK NEOPLASMS; HEDGEHOG PROTEINS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 84953358346     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2015.11.014     Document Type: Article

References (19)

1. B. Burtness, J.E. Bauman, and T. Galloway Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition Lancet Oncol 14 2013 e302 309
2. M.E.P. Prince, and L.E. Ailles Cancer stem cells in head and neck squamous cell cancer J Clin Oncol 26 2008 2871 2875
3. R. Kalluri, and R.A. Weinberg The basics of epithelial-mesenchymal transition J Clin Invest 119 2009 1420 1428
4. E. Pectasides, T. Rampias, and C. Sasaki Markers of epithelial to mesenchymal transition in association with survival in head and neck squamous cell carcinoma (HNSCC) PLoS One 9 2014 e94273
5. G. Feldmann, S. Dhara, and V. Fendrich Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers Cancer Res 67 2007 2187 2196
6. S. Liu, G. Dontu, and I.D. Mantle Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells Cancer Res 66 2006 6063 6071
7. C.H. Chung, J.J. Dignam, and M.E. Hammond Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003) J Clin Oncol 29 2011 1326 1334
8. G.N. Gan, J. Eagles, and S.B. Keysar Hedgehog signaling drives radioresistance and stroma-driven tumor repopulation in head and neck squamous cancers Cancer Res 74 2014 7024 7036
9. N. Isohata, K. Aoyagi, and T. Mabuchi Hedgehog and epithelial-mesenchymal transition signaling in normal and malignant epithelial cells of the esophagus Int J Cancer 125 2009 1212 1221
10. H. Schnidar, M. Eberl, and S. Klingler Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway Cancer Res 69 2009 1284 1292
11. S.B. Keysar, P.N. Le, and R.T. Anderson Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer Cancer Res 73 2013 3381 3392
12. A. Jimeno, G.J. Weiss, and W.H. Miller Jr. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors Clin Cancer Res 19 2013 2766 2774
13. S.B. Keysar, D.P. Astling, and R.T. Anderson A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins Mol Oncol 7 2013 776 790
14. J.B. Vermorken, J. Trigo, and R. Hitt Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy J Clin Oncol 25 2007 2171 2177
15. Ko AH, LoConte N, Tempero MA et al. A phase I study of FOLFIRINOX plus IPI-926, a Hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma. Pancreas; 2015.
16. J.B. Vermorken, J. Stohlmacher-Williams, and I. Davidenko Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial Lancet Oncol 14 2013 697 710
17. R.N. Amaria, D.W. Bowles, K.D. Lewis, and A. Jimeno Vismodegib in basal cell carcinoma Drugs Today (Barc) 48 2012 459 467
18. X. Yang, X. Zhang, and E.D. Mortenson Cetuximab-mediated tumor regression depends on innate and adaptive immune responses Mol Ther 21 2013 91 100
19. R.M. Srivastava, S.C. Lee, and P.A. Andrade Filho Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients Clin Cancer Res 19 2013 1858 1872